You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Populating MPS database with data from multi-organ, human-on-a-chip microphysiological systems
SBC: HESPEROS, INC Topic: 100Project Summary/Abstract: As stated in the Notice of Special Interest announcement, there is a need to populate the recently established MPS database with existing data generated by organ-on-a-chip systems. Having a centralized, public database with data from all available MPS systems will accelerate development and acceptance of the technology ultimately bringing better therapies to patients fast ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty
SBC: Longeveron LLC Topic: NIAAging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomes. Frailty has an overall prevalence of 10% of those 65 years and older, and there is growing awareness in the geriatric community to diagnose and treat this condition, as it is not an inevitable ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Functional integrated human-on-a-chip systems for Alzheimer's research
SBC: HESPEROS, INC Topic: NIAProject SummaryThe goal of this proposal, at the end of the Phase II effort, is to have a service available to academia and industry to screen drugs for Alzheimer’s to predict patient outcomes and determine how potential therapeutics are delivered to the CNS. There are currently few companies able to offer multi-organ evaluation with a recirculating medium utilizing functional readouts, and none ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
SBC: SCARAB GENOMICS, LLC Topic: NIAIDScarab Genomics has established a unique, tiny footprint, extended bacterial fermentation process enabled by its reduced genome E. coli, for production of protein therapeutics, especially vaccine conjugates. The process will massively reduce the cost and upgrade the quality of these critical vaccine components. This Phase IIB resubmission focuses on commercial development of Scarab’s first vacci ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
A computational platform to improve the prioritization of drugs and target genes for therapeutic intervention
SBC: Genetic Networks, LLC Topic: 100Project Summary This project proposes further development of a computational discovery platform shown to quantifiably identify and prioritize both targets and compounds for therapeutic intervention, which will accelerate the development of newer, more effective drugs with fewer side-effects. This platform is based on a novel fusion of two state of the art computational approaches (phenolog mapping ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting glioblastoma stem-like cells with custom-designed viral vectors
SBC: Lacerta Therapeutics, Inc. Topic: 102Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Product Development of Intensity Modulation for Bolus Electron Conformal Therapy
SBC: Decimal, LLC Topic: 102Project Summary/Abstract Objective: This project aims to elevate electron beam therapy (EBT) technology, which provides effective radiation treatment for superficial cancers (depthandlt;6 cm), to that of other external beam radiotherapies (XRT), e.g. x-rays and protons, by bringing electron intensity modulation into the clinic. Challenge: Approximately 10% of radiotherapy patients (173,000 in U ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)
SBC: Stemsynergy Therapeutic Topic: 102ABSTRACT Individuals with the rare, inherited disorder Familial Adenomatous Polyposis (FAP) develop thousands of precancerous polyps at an early age and ultimately develop colorectal cancer (CRC). The current standard of care for FAP is colectomy. However, unavoidable side-effects of colectomy are debilitating. Furthermore, colectomy does not prevent subsequent development of extra-colonic intesti ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
HLS-Cardiac Safety AI Trained Human Heart and Micro Heart Model
SBC: Invivosciences, Inc. Topic: NHLBIHLS17-12. The US FDA is considering to establish a new cardiac safety assessment approachdefined by a new paradigm called, “Comprehensive in vitro Proarrhythmia Assay (CIPA)”. The CIPA will 1) assess drug effects on each cardiac ion channel type individually using a high- throughput assay ion channel assays, 2) compute net effect on repolarization and risks fortorsade pointes (TdP) using a mat ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Ultrathin Dissolvable Antibiofilm Wound Contact Dressing with Silver and Gallium
SBC: IMBED BIOSCIENCES INC Topic: NIAMSThe entire Research Plan contains proprietary/privileged information that Imbed Biosciences requests not be released to persons outside the Government, except for purposes of review and evaluation. SUMMARY The health care costs associated with treatment of chronic wounds exceeds $25 billion annually in the U.S. Biofilms are implicated as a key factor responsible for delayed healing. Many wounds ha ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health